Pre-made Alnuctamab benchmark antibody (Bispecific mAb with Domain Crossover, anti-TNFRSF17;CD3E therapeutic antibody, Anti-BCM/BCMA/CD269/TNFRSF13A;T3E/TCRE/IMD18 Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-018

Pre-made Alnuctamab benchmark antibody (Bispecific mAb with Domain Crossover, anti-TNFRSF17;CD3E therapeutic antibody, Anti-BCM/BCMA/CD269/TNFRSF13A;T3E/TCRE/IMD18 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.



Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-018-1mg 1mg Inquiry
GMP-Bios-ab-018-10mg 10mg Inquiry
GMP-Bios-ab-018-100mg 100mg Inquiry
GMP-Bios-ab-018-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:

For more than 100mg, click here for inquiry. >>


Description

Products Name (INN Index) Pre-Made Alnuctamab biosimilar, Bispecific mAb with Domain Crossover, Anti-TNFRSF17;CD3E Antibody: Anti-BCM/BCMA/CD269/TNFRSF13A;T3E/TCRE/IMD18 therapeutic antibody
INN Name Alnuctamab
TargetTNFRSF17;CD3E
FormatBispecific mAb with Domain Crossover
DerivationBispecific antibody
Species ReactivityHuman
CH1 IsotypeIgG1;G1
VD LCKappa;Lambda
Highest_Clin_Trial (Jan '20)Phase-I
Est. StatusActive
100% SI StructureNone;None
99% SI StructureNone;None
95-98% SI StructureNone;None
Year Proposed2020
Year Recommended2021
CompaniesCelgene Corporation
Conditions Approvedna
Conditions ActiveMultiple myeloma
Conditions Discontinuedna
Development Techna